|
NEU3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6304735339645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.4749538236365E-12 |
| Normal-vs-Stage2 |
4.7772000000279E-06 |
| Normal-vs-Stage3 |
1.21092025295866E-12 |
| Normal-vs-Stage4 |
4.56830018258358E-10 |
| Stage1-vs-Stage2 |
5.441600E-01 |
| Stage1-vs-Stage3 |
2.082200E-01 |
| Stage1-vs-Stage4 |
1.647410E-01 |
| Stage2-vs-Stage3 |
1.433210E-01 |
| Stage2-vs-Stage4 |
1.383380E-01 |
| Stage3-vs-Stage4 |
8.034400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.13353770814228E-13 |
| Normal-vs-AfricanAmerican |
2.195100E-04 |
| Normal-vs-Asian |
2.36530000030655E-08 |
| Caucasian-vs-AfricanAmerican |
4.580000E-01 |
| Caucasian-vs-Asian |
7.285800E-01 |
| AfricanAmerican-vs-Asian |
3.394200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.32858218555066E-13 |
| Normal-vs-Female |
1.9462209621679E-12 |
| Male-vs-Female |
1.965380E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.48870052238703E-10 |
| Normal-vs-Age(41-60Yrs) |
6.213918268827E-13 |
| Normal-vs-Age(61-80Yrs) |
7.89690535185628E-11 |
| Normal-vs-Age(81-100Yrs) |
3.831000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.073000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.269200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.744600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.439600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.131800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.802000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.692200E-02 |
| Classical-VS-Follicular |
4.031600E-02 |
| Classical-VS-Other |
9.550300E-02 |
| Classical-VS-Normal |
1.45840006737785E-11 |
| Tall-VS-Follicular |
6.676800E-01 |
| Tall-VS-Other |
4.017400E-01 |
| Tall-VS-Normal |
2.62050003918546E-09 |
| Follicular-VS-Other |
3.611800E-01 |
| Follicular-VS-Normal |
9.79869518857868E-11 |
| Other-VS-Normal |
2.838700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.03104241495112E-13 |
| Normal-vs-N1 |
3.61410013027808E-10 |
| N0-vs-N1 |
2.398800E-01 |
|
|
